Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Government BANS use of...

    Government BANS use of decade old antibiotic COLISTIN in animal feeding, fishing

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-22T15:24:39+05:30  |  Updated On 22 July 2019 3:24 PM IST
    Government BANS use of decade old antibiotic COLISTIN in animal feeding, fishing

    New Delhi: Through a recent Gazette notification, the Union Health Ministry has imposed a ban on popular antibiotic Colistin and its formulations in food-producing animals, poultry and aquafarms, with immediate effect. The move is likely to preserve the drug's efficacy in humans and keep a check on the growing menace of antimicrobial resistance (AMR) in humans through animals here.


    The Government has also directed manufacturers of Colistin to specify “in a conspicuous manner” on the labels, package inserts and promotional literature that these products are “not to be used in food-producing animals, poultry, aqua farming and animal feed supplements”


    The decision comes following the advice of the country’s apex advisory board, Drugs Technical Advisory Board (DTAB), on issues related to the pharmaceutical sector. The Ministry of Health and Family Welfare had reportedly been contemplating to prohibit the use of colistin in animals for long.


    Also Read: 80 more Fixed Dose Drugs including Antibiotics, Hypertension Combos Banned by Health Ministry


    Colistin is given to chickens and other farm animals to make them gain weight faster and as pre-emptive protection against disease. The antibiotic is also used as a last line of defence in humans whose infections are not responding to other drugs. However, the decades-old drug fell out of favour in human medicine due to its kidney toxicity.


    A senior health ministry official told PTI, “Colistin is an antibiotic for therapeutic purpose in veterinary. But the drug is highly misused in the poultry industry as a growth promoter for prophylactic purpose. One of the reasons for antibiotic resistance in India is due to unwanted use of Colistin in the poultry industry. This notification will prevent the use of the drug for prophylactic use.”


    "It is brought to the notice of the Central Government that the use of the drug Colistin and its formulations for food-producing animals, poultry, aqua farming and animal feed supplements is likely to involve risk to human beings;


    Therefore;


    In exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government issued an order that seeks to prevent the use of Colistin for prophylactic purposes and mandate it for the manufacturers to write clearly on the label that the drug is not to be used in food-producing animals, poultry, aqua farming and animal-feed supplement.




    prohibits the manufacture, sale and distribution of the following drug with immediate effect, namely:― “Colistin and its formulations for food-producing animals, poultry, aqua farming and animal feed supplements”; and


    directs that the manufacturer of Colistin and its formulations shall label the container of the drug and mention the words “NOT TO BE USED IN FOOD PRODUCING ANIMALS, POULTRY, AQUA FARMING AND ANIMAL FEED SUPPLEMENTS” in conspicuous manner on the package insert and promotional literature of the said drug and its.



    The European Union reportedly banned colistin in 2006, Malaysia and China joined the list in 2018 and do not permit the use of the antibiotic, both for therapeutic and growth promotion in animals.


    A couple of years ago, an exhaustive scientific study raised concern of the menace of the widespread misuse of the antibiotics in the poultry sector.


    As per a media report by the Deccan Herald, one of the studies conducted in India collected over 1500 samples from 530 birds in 18 poultry farms in six districts in Punjab. The samples were tested for resistance to a range of antibiotics critical to human medicine. Surprisingly, two-thirds of the farms reported using antibiotics like Colistin to boost growth.


    “The central government is satisfied that it is necessary and expedient in the public interest to prohibit the drug for animal-rearing,” the gazette notification added.


    Backing the present decision, a government researcher, requesting anonymity told HT, “Misuse of last-resort antibiotics such as colistin is a major concern as it fuels antimicrobial resistance that’s a global concern. It is a step in the right direction.”

    antibiotic colistinantibioticsaqua farmbanchinacolistinColistin banColistin ban Indiacolistin noticecolistin useEUfisheriesgazette notificationGazette of Indiagovernmentlivestock farmingMalaysiaMinistry of Health and Family Welfarepoultry farming
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok